News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu/X
May 1, 2025, 09:14

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

  • 12-wk PFS: 42%.
  • ORR: 25%.
  • Median DOR: 13.1 mo.
  • Median OS: 14.8 mo.”

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis
Special Coverage
Voices
Aug 21, 2025, 20:00
Raymond Mailhot: Advancing Hodgkin Lymphoma Survivor Study with NCI Funding
Voices
Aug 21, 2025, 19:28
Parvati Tiwari: Advocates Express Alarm Over NCI’s Decision to End PBTC Funding for Pediatric Brain Tumor Trials
Voices
Aug 21, 2025, 15:59
George Kumar: The interplay Between Cardiovascular Disease (CVD) and Cancer
Voices
Aug 21, 2025, 15:47
European Society of Gynaecological Oncology Announces that Applications are Open for Editor-in-Chief of IJGC
Insight
Aug 21, 2025, 15:37
Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer
Voices
Aug 21, 2025, 15:30
Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore
Voices
Aug 21, 2025, 15:22
Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion
Oncolibrary
Aug 21, 2025, 15:00
Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule
Voices
Aug 21, 2025, 14:50
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024
Insight
Aug 21, 2025, 14:47
Loay Kassem: Study Reveals BRCA Mutation Rates in Egyptian Women with Breast or Ovarian Cancer
Insight
Aug 21, 2025, 14:41
Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment
Voices
Aug 21, 2025, 14:40
Larissa Nekhlyudov Celebrates Leadership of Emily Smith Tonorezos and Michelle Mollica in Cancer Survivorship